The lower R & D expenses reflected the elimination of manufacturing expenses following the sale of our follow-on biologics ( " FOB " ) assets in March 2009 . The increase in SG & A expenses was due to a combination of external finance and consulting advisory services associated with the ongoing strategic review , increased personnel costs , primarily related to the separation agreement with Geoffrey Allan , Ph.D. , and license fees relating to the March 2007 patent settlement agreement with Genentech Inc. and Tercica Inc .